Mechanistic insights into Old English plants

Jasminum humile inhibits calcineurin. Credit: Geoffrey Kite

Often lacking in natural product drug discovery are ‘mechanistic insights’; that is, insights into the events at the molecular level that are behind any effects that plant compounds have on cells or organisms. With this in mind, Tom Prescott screened 250 Old English plants from the Queen’s Garden at Kew, to search for compounds that inhibit the human enzyme calcineurin. The results have been published in the Journal of Ethnopharmacology.

Calcineurin plays an important role in regulating human T-cell activation in the immune response, and inhibition of this process can be beneficial in certain auto-immune diseases.

Nepeta cataria and Teucrium chamaedrys showed initial promise but the compounds responsible (phenylpropanoid glycosides) were only strongly active against the basal, un-activated form of the enzyme.

Jasminum humile was found to be more promising as the ethanol extract inhibited both isolated human calcineurin enzyme and calcineurin-dependent gene expression in yeast cells. This demonstrated that plants do indeed produce compounds that directly inhibit .

More information: Prescott, T. A. K., et al. (2011). Direct inhibition of calcineurin by caffeoyl phenylethanoid glycosides from Teucrium chamaedrys and Nepeta cataria. Journal of Ethnopharmacology 137: 1306–1310.

Prescott, T. A. K., et al. (2012). Inhibition of human calcineurin and yeast calcineurin-dependent gene expression by Jasminum humile leaf and root extracts. Journal of Ethnopharmacology 140: 293-297.

add to favorites email to friend print save as pdf

Related Stories

Time to stop giving toxic drugs to kidney transplant patients?

Sep 22, 2011

Patients who receive kidney transplants must take lifelong medications that, while preventing organ rejection, can also compromise other aspects of health. Immunosuppresive drugs called calcineurin inhibitors protect transplanted ...

Recommended for you

Ebola vaccine not before late 2016: GSK researcher

Oct 17, 2014

An Ebola vaccine by British pharmaceuticals giant GlaxoSmithKline may not be ready for commercial use until late 2016 and should therefore not be seen as the "primary answer" to the current outbreak, a company researcher ...

Chimerix gets FDA OK to test drug for Ebola

Oct 17, 2014

(AP)—A North Carolina drugmaker plans to test its experimental antiviral drug in patients who have Ebola, after getting authorization from regulators at the Food and Drug Administration.

Esbriet, ofev approved to treat deadly lung disease

Oct 16, 2014

(HealthDay)—Two new drugs have been approved by the U.S. Food and Drug Administration to treat progressive lung scarring from an uncertain cause, medically called idiopathic pulmonary fibrosis (IPF).

FDA weighs removing bolded warning from Chantix

Oct 14, 2014

(AP)—The Food and Drug Administration will ask a panel of experts later this week whether a bold-letter warning on the anti-smoking drug Chantix should be removed based on company-supported evidence that the drug does not ...

Drug-coated balloon catheter approved

Oct 13, 2014

(HealthDay)—The first drug-coated balloon catheter designed to clear narrowed or blocked arteries in the thigh and knee has been approved by the U.S. Food and Drug Administration.

User comments